Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Proteomics Firm Geneka to Open Base in France

NEW YORK, Nov. 13 — Geneka Biotechnology will be opening an office in Strasbourg, France, toward the start of the new year, the company announced on Tuesday. 

The new office, which represents the company’s first international expansion, will be small at first and will have no associated lab space, said Jean Rousseau, director of international marketing and sales at Montreal-based Geneka. 

The company chose Strasbourg for its central location and proximity to Germany, Switzerland, and the Alsace region in western France, where a lot of important research into transcription factors is carried out, added Rousseau. 

“The concentration of the market is there for us,” he said. 

Geneka, which focuses on proteomic regulators, including transcription factors, co-activators, co-repressors, and chromatin associated proteins, will be recruiting locally to fill the new office.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.